Raymond James Financial Services Advisors, Inc. Alaunos Therapeutics, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$0.46 - $0.81 $7 - $12	-16 Reduced 0.11%	14,570 $9,000
Q4 2022 Feb 08, 2023	SELL	$0.5 - $261.0 $2,861 - $1.49 Million	-5,723 Reduced 28.18%	14,586 $9,000
Q3 2022 Oct 25, 2022	SELL	$1.04 - $322.5 $27 - $8,385	-26 Reduced 0.13%	20,309 $35,000
Q2 2022 Aug 12, 2022	BUY	$0.41 - $1.24 $2,665 - $8,060	6,500 Added 46.98%	20,335 $25,000
Q1 2022 May 11, 2022	SELL	$0.62 - $1.17 $4,340 - $8,189	-7,000 Reduced 33.6%	13,835 $9,000
Q4 2021 Feb 08, 2022	SELL	$1.09 - $1.89 $3,892 - $6,749	-3,571 Reduced 14.63%	20,835 $23,000
Q3 2021 Nov 02, 2021	BUY	$1.44 - $2.73 $6,638 - $12,585	4,610 Added 23.29%	24,406 $44,000
Q2 2021 Aug 11, 2021	SELL	$2.63 - $3.67 $11,766 - $16,419	-4,474 Reduced 18.43%	19,796 $52,000
Q1 2021 May 14, 2021	BUY	$2.82 - $5.6 $17,382 - $34,518	6,164 Added 34.04%	24,270 $87,000
Q4 2020 Feb 12, 2021	SELL	$2.09 - $3.09 $647 - $957	-310 Reduced 1.68%	18,106 $46,000
Q3 2020 Nov 04, 2020	SELL	$2.39 - $3.43 $3,346 - $4,802	-1,400 Reduced 7.06%	18,416 $46,000
Q1 2020 Apr 21, 2020	SELL	$1.9 - $4.98 $8,523 - $22,340	-4,486 Reduced 18.46%	19,816 $49,000
Q4 2019 Feb 12, 2020	BUY	$3.95 - $5.35 $95,992 - $130,015	24,302 New	24,302 $115,000
Q3 2019 Nov 07, 2019	SELL	$4.13 - $6.94 $221,483 - $372,178	-53,628 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$3.98 - $6.2 $38,168 - $59,458	9,590 Added 21.78%	53,628 $313,000
Q1 2019 May 06, 2019	SELL	$2.0 - $4.4 $5,774 - $12,702	-2,887 Reduced 6.15%	44,038 $170,000
Q4 2018 Feb 11, 2019	BUY	$1.61 - $3.62 $75,549 - $169,868	46,925 New	46,925 $88,000
Q3 2018 Nov 14, 2018	SELL	$2.26 - $3.27 $318,872 - $461,377	-141,094 Closed	0 $0
Q2 2018 Jul 30, 2018	SELL	$3.02 - $4.94 $35,602 - $58,237	-11,789 Reduced 7.71%	141,094 $426,000
Q1 2018 Apr 16, 2018	BUY	$3.46 - $5.14 $12,085 - $17,954	3,493 Added 2.34%	152,883 $599,000
Q4 2017 Feb 09, 2018	BUY	$4.0 - $6.54 $45,568 - $74,503	11,392 Added 8.26%	149,390 $618,000
Q3 2017 Oct 26, 2017	BUY	$4.99 - $6.57 $31,317 - $41,233	6,276 Added 4.76%	137,998 $847,000
Q2 2017 Aug 15, 2017	BUY	N/A	131,722	131,722 $819,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account